Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 11,349 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Development and Feasibility of Mindfulness Based Pain Reduction

NCT04980612
Conditions
Chronic Low-back Pain
Interventions
Mindfulness Based Pain Reduction, Mindfulness Based Stress Reduction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Withdrawn No phase listed Observational

Omics of Cancer: OncoGenomics

NCT05431439
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Interventions
G207
Biological
Lead sponsor
Gregory K. Friedman, MD
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Conditions
Alcohol-Related Disorders
Interventions
Dihydromyricetin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Interventions
KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions
IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Austin, Texas • Irving, Texas • San Antonio, Texas
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
320,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study on Sarilumab-exposed Pregnancies

NCT03378219
Conditions
Rheumatoid Arthritis -Exposure During Pregnancy
Interventions
Sarilumab SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations
Interventions
SRK-015
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more
Conditions
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions
PF-02341066, Rifampin, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
24
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Conditions
Enterovirus Infection
Interventions
Placebo, Pleconaril
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 15 Days
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

NCT01603147
Conditions
Methamphetamine Abuse
Interventions
normal saline, ch-mAb7f9
Biological
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Breast
Interventions
QT Ultrasound scan
Device
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
755 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Long Beach, California • Novato, California
Completed Phase 1 Interventional Results available

A Study of IMC-RON8 in Advanced Solid Tumors

NCT01119456
Conditions
Cancer
Interventions
IMC-RON8
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Detroit, Michigan • New York, New York
Conditions
Weakness, Hospital Acquired Condition
Interventions
Ambulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Kidney Transplant Rejection
Interventions
Retrospective Cohort Enrollment, Prospective Cohort Enrollment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures

NCT01564407
Conditions
Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
Interventions
ICX-RHY-013
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Riverside, California • San Francisco, California • Sanford, Florida + 8 more
Conditions
Typhoid Fever
Interventions
Vivotif
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more